Literature DB >> 20055840

Acute generalized exanthematous pustulosis induced by itraconazole: an immunological approach.

G G L Cançado1, R T Fujiwara, P A Freitas, R Correa-Oliveira, J M Bethony.   

Abstract

Acute generalized exanthematous pustulosis (AGEP) is an uncommon disease, which presents as a nonfollicular erythematous sterile pustular eruption. More than 90% of the cases are induced by adverse drug reactions, often triggered by anti-infectious systemic drugs. We report a case of itraconazole-induced AGEP in a 22-year-old man, with an assessment of his cytokine/chemokine production and drug-specific cell reactivity. We found that AGEP, like other T cell-mediated drug eruptions, alters the immunological status of the patient, probably favouring T-cell activation, recruitment and regulation. Few cases of itraconazole-induced AGEP have been described in the literature, and to our knowledge, this is the first report in which the cellular immunological features are assessed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20055840     DOI: 10.1111/j.1365-2230.2009.03440.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  3 in total

1.  Fluconazole-induced acute generalized exanthematous pustulosis.

Authors:  Vito Di Lernia; Cinzia Ricci
Journal:  Indian J Dermatol       Date:  2015 Mar-Apr       Impact factor: 1.494

2.  Subcorneal Pustular Dermatosis Exhibiting a High Serum TARC/CCL17 Level.

Authors:  Sachiko Ono; Atsushi Otsuka; Yoshiki Miyachi; Kenji Kabashima
Journal:  Case Rep Dermatol       Date:  2013-02-21

3.  Drug Adverse Event Detection in Health Plan Data Using the Gamma Poisson Shrinker and Comparison to the Tree-based Scan Statistic.

Authors:  Jeffrey S Brown; Kenneth R Petronis; Andrew Bate; Fang Zhang; Inna Dashevsky; Martin Kulldorff; Taliser R Avery; Robert L Davis; K Arnold Chan; Susan E Andrade; Denise Boudreau; Margaret J Gunter; Lisa Herrinton; Pamala A Pawloski; Marsha A Raebel; Douglas Roblin; David Smith; Robert Reynolds
Journal:  Pharmaceutics       Date:  2013-03-14       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.